Adherium exceeds CY2025 device shipment milestones
Filed with ASX · · 4 pages · English
• This shipment milestone represents the most operationally significant growth objective for Adherium in CY2025 – with strong, repeatable device uptake forecast for the New Year and beyond. Melbourne, Australia – 24 December 2025: Adherium Limited (ASX:ADR), a global leader in digital respiratory management and developer of the US FDA-cleared Hailie® Smartinhaler® platform is pleased to announce t
Earlier from Adherium
- Adherium quarter to date sales update
- Adherium reaches major milestone in Allergy Partners rollout
- Adherium's Hailie® Smartinhaler® Chosen for Groundbreaking iCARE Study: Significant Adherence, Consistent Outcomes, and Global Health System Savings
- iCARE Study Hailie Smartinhaler Improves Patient Adherence
- New Data, iCARE Study: Hailie® Smartinhaler® Powers Unprecedented Medication Adherence in Patients with COPD and Asthma
Later from Adherium
- Quarterly Activities/Appendix 4C Cash Flow Report
- Trading Halt
- Equity Raising Investor Presentation
- Placement and Accelerated Non-Renounceable Entitlement Offer
- Completion of Placement and Institutional Entitlement Offer
Follow Adherium into a list and get an email when it puts out news.
Follow Adherium